drugset / Trial / NCT00451815
BIIB014 Phase 2a Monotherapy
RandomizedParallel-groupTreatment
Summary
To assess the preliminary safety and tolerability of multiple oral doses of BIIB014 in subjects with early PD.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VIPADENANT | Small molecule | 10 mg | Oral |
| Subject | VIPADENANT | Small molecule | 30 mg | Oral |
| Subject | VIPADENANT | Small molecule | 100 mg | Oral |
| Subject | VIPADENANT | Small molecule | 300 mg | Oral |